Outcomes of Robot-assisted Radical Prostatectomy with the Hugo RAS Surgical System: Initial Experience at a High-volume Robotic Center

We describe surgical outcomes for patients undergoing robot-assisted radical prostatectomy performed with the Hugo RAS system at a high-volume robotic center. While we await studies with longer follow-up, our experience demonstrates that this platform provides adequate results with respect to surgical pathology and early recovery of urinary continence. Clinical data on robot-assisted radical prostatectomy (RARP) performed with the new Hugo robot-assisted surgery (RAS) system are scarce. We described surgical outcomes of 112 consecutive patients who underwent RARP ± extended pelvic lymph-node dissection (ePLND) at OLV Hospital (Aalst, Belgium) between February and November 2022. The median age was 65 yr (interquartile range [IQR] 60–70) and median preoperative prostate-specific antigen (PSA) was 7.9 ng/ml (5.8–10.7). Thirty-eight patients (34%) had International Society of Urological Pathology grade group ≥3 tumor on prostate biopsy. On preoperative magnetic resonance imaging, 26 (23%) patients had a suspicion of extraprostatic disease. The median operative time was 180 min (IQR 145–200) and 27 men (24%) underwent ePLND. On final pathology, 34 patients (31%) had extraprostatic disease and ten (9%) had positive surgical margins. The median number of nodes removed was 15 (IQR 9–19). Among men with data available on the first PSA after surgery, 88% (60/68) had undetectable PSA (